The promise of ESCAT: a new system for evaluating cancer drug-target pairs

Nat Rev Clin Oncol. 2019 Mar;16(3):147-148. doi: 10.1038/s41571-018-0110-3.

Authors

Bishal Gyawali¹, Aaron S Kesselheim²

Affiliations

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. bg.bishalgyawali@gmail.com.
² Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

PMID: 30317250
DOI: 10.1038/s41571-018-0110-3

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / genetics*
Humans
Molecular Targeted Therapy
Mutation
Neoplasms / drug therapy*
Precision Medicine

Substances

Antineoplastic Agents
Biomarkers, Tumor